Back

The efficacy and safety of macitentan in Fontan-palliated patients: results of the 52-week randomised, placebo-controlled RUBATO trial

26 August 2022 (12:15 - 12:40)
Organised by:
Congress Presentation Part of: Focus on the pulmonary vascular bed Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Paul Clift

Queen Elizabeth Hospital Birmingham, Birmingham (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Ventricular-arterial coupling predicts outcomes in adults with a systemic right ventricle
Doctor G. Pasqualin (Milan, IT)
Abstract Slides
Presentation thumbnail
Inactivation of catalytic and non-catalytic PI3 kinase gamma functions enhances hypoxia-induced pulmonary hypertension in mice
Mrs L. Gnatzy-Feik (Cologne, DE)
Abstract Slides
Presentation thumbnail
Investigating monotherapy and combination therapy trends in newly diagnosed patients with pulmonary arterial hypertension among EU3 & UK physicians over the COVID-19 pandemic.
Mr D. Chandler (London, GB)
Abstract Slides
Presentation thumbnail
Efficacy and safety of selexipag in real-life in patients with pulmonary arterial hypertension: early results of RAMPHA study
Doctor R. Bravo-Marques (Marbella, ES)
Abstract Slides

Access the full session

Session thumbnail
Focus on the pulmonary vascular bed

The Event

Event poster

ESC Congress 2022

26 August 2022 12:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources